Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Sarcoma, Ewing × Temozolomide × Clear all

Phase

Status

Recruiting 6 Completed 6 Terminated 2 Active not recruiting 2 Withdrawn 1 Unknown 1 Not yet recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Glioblastoma 38 Glioma 14 Melanoma 10 Astrocytoma 10 Central Nervous System Neoplasms 8 Brain Neoplasms 8 Oligodendroglioma 6 Gliosarcoma 4 Leiomyosarcoma 3 Sarcoma 2 Recurrence 2 Neoplasms, Neuroepithelial 2 Neoplasm Metastasis 2 Diffuse Intrinsic Pontine Glioma 2 Breast Neoplasms 2 Uveal Melanoma 1 Small Cell Lung Carcinoma 1 Sarcoma, Synovial 1 Sarcoma, Ewing 1 Sarcoma, Endometrial Stromal 1 Sarcoma, Alveolar Soft Part 1 Rhabdomyosarcoma 1 Rhabdoid Tumor 1 Recurrent Extensive Stage Small Cell Lung Carcinoma 1 Rectal Neoplasms 1 Pituitary Neoplasms 1 Pheochromocytoma 1 Paraganglioma 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1

Interventions

Cyclophosphamide 3 seclidemstat 2 Topotecan 2 Drug Therapy 2 irinotecan sucrosofate 1 anlotinib 1 Vorinostat 1 Vinorelbine 1 Vincristine 1 Triptorelin Pamoate 1 Trabectedin 1 Temozolomide 1 TQ-B3525 1 Irinotecan 1 Biological Factors 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03359005 2022-11-01

Irinotecan and Temozolomide for Ewing Sarcoma

Peking University People's Hospital

Phase 2 Unknown

Sarcoma, Ewing

Data powered by HemOnc (CC BY 4.0) Colophon ⚡